Autoimmunity, Transplantation & Inflammatory Disease

Our Autoimmunity, Transplantation & Inflammatory (ATI) disease strategy is to move from general immuno-suppressants to selective immuno-modulators. Discovery efforts focus on modulating dysregulated immune responses by targeting immune cell activation, expansion, regulation, trafficking and effector functions with both small molecule compounds and monoclonal antibodies.

Our ATI research focuses on diseases with multiple aberrant disease pathways and those that share the same disease pathways. Intervening in such pathways offers opportunities to treat several diseases with the same treatment approach and provides opportunities for rational combination therapies with increased efficacy and decreased side effects.

We concentrate on autoimmune and inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, psoriasis and systemic lupus erythematosus, as well as transplant rejection.